5051-62-7 Usage
Uses
Used in Pharmaceutical Industry:
Guanabenz is used as an alpha agonist for treating various degrees of hypertension. It helps in reducing blood pressure by decreasing the overall peripheral vascular resistance, which in turn leads to a decline in the frequency of cardiac contractions and reduced cardiac output.
Used in Combination Therapy:
Guanabenz is also used in combination with oral diuretics to enhance the treatment of hypertension. This combination therapy allows for a more effective management of blood pressure levels, particularly in cases where monotherapy may not be sufficient.
Originator
Wytensin,Wyeth,US,1982
Manufacturing Process
A mixture of 14.0 g of 2,6-dichlorobenzaldehyde, 10.8 g of aminoguanidine
bicarbonate and 100 ml of pyridine was refluxed for 3 hours. The reaction
mixture was poured into water and the crystalline precipitate filtered off; MP
225°C to 227°C.
Therapeutic Function
Antihypertensive
Synthesis
Guanabenz, [(2,6-dichlorobenzyliden) amino] guanidine (22.3.1), is synthesized
in one step by reacting 2,6-dichlorobenzaldehyde with amino guanidine.
Purification Methods
Crystallise the guanidine from MeCN and store it in a CO2–free atmosphere. The monoHCl [23256-5-0] has m 178o(dec) [solubility w% at 25o is 1.1(H2O), 5(EtOH), 0.1(EtOAc), 0.06(CHCl3)]. It is an antihypertensive drug. [Holmes et al. Drugs 26 212 1983.]
Check Digit Verification of cas no
The CAS Registry Mumber 5051-62-7 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 5,0,5 and 1 respectively; the second part has 2 digits, 6 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 5051-62:
(6*5)+(5*0)+(4*5)+(3*1)+(2*6)+(1*2)=67
67 % 10 = 7
So 5051-62-7 is a valid CAS Registry Number.
InChI:InChI=1/C8H8Cl2N4/c9-6-2-1-3-7(10)5(6)4-13-14-8(11)12/h1-4H,(H4,11,12,14)/b13-4+
5051-62-7Relevant articles and documents
The fourth molybdenum containing enzyme mARC: Cloning and involvement in the activation of N-hydroxylated prodrugs
Gruenewald, Sanja,Wahl, Bettina,Bittner, Florian,Hungeling, Helen,Kanzow, Stephanie,Kotthaus, Joscha,Schwering, Ulrike,Mendel, Ralf R.,Clement, Bernd
scheme or table, p. 8173 - 8177 (2009/12/07)
The recently discovered mammalian molybdoprotein mARC1 is capable of reducing N-hydroxylated compounds. Upon reconstitution with cytochrome b 5 and b5 reductase, benzamidoxime, pentamidine, and diminazene amidoximes, N-hydroxymelagatran, guanoxabenz, and N-hydroxydebrisoquine are efficiently reduced. These substances are amidoxime/N-hydroxyguanidine prodrugs, leading to improved bioavailability compared to the active amidines/guanidines. Thus, the recombinant enzyme allows prediction about in vivo reduction of N-hydroxylated prodrugs. Furthermore, the prodrug principle is not dependent on cytochrome P450 enzymes.
Substituted benzylidene hydrazines for treating hyperglycemia, obesity and inflammation
-
, (2008/06/13)
Substituted benzylidene hydrazines e.g. N-(4-phenylbenzylidene)-N'-amidino hydrazine and their use as hypoglycemic-antihyperglycemic agents, anti-obesity agents and anti-inflammatory agents.
Therapeutic agents
-
, (2008/06/13)
O-HALOBENZYLIDENEAMINOGUANIDINES ARE EMPLOYED AS CENTRAL NERVOUS SYSTEM DEPRESSANTS, AS CARDIOVASCULAR DEPRESSANTS, AND/OR AS ANTIDEPRESSANTS FOR OVERCOMING PSYCHIC DEPRESSION.
